Impairment loss on certain product plans in the metabolomics business
First written in FY2019. 4 of 4 entries say "Materialised", first in FY2019. Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024MaterialisedAnnual report
「As a result of reviewing the outlook, we have not calculated a specific discount rate because the future cash flows are negative.」
The Group recognised an impairment loss of ¥624 thousand on inspection and measurement equipment in Chuo-ku, Tokyo because it was determined to be unrecoverable. - FY2022MaterialisedAnnual report
「During the consolidated fiscal year under review, the Group recognised an impairment loss on the following asset group: Chuo-ku, Tokyo, inspection and measurement equipment, tools, furniture and fixtures, ¥248 thousand.」
The Group recognised an impairment loss of ¥248 thousand on inspection and measurement equipment in Chuo-ku, Tokyo because recovery of the future cash flows could not be expected. - FY2021MaterialisedAnnual report
「During the consolidated fiscal year under review, the Group recognised impairment losses on the following asset groups: inspection and measurement equipment in Chuo-ku, Tokyo (software), ¥428 thousand; office equipment in the Netherlands (tools, furniture and fixtures), ¥456 thousand; total, ¥885 thousand.」
The Group recognised total impairment losses of ¥885 thousand on assets related to the metabolomics and European businesses because recovery of the future cash flows could not be expected. - FY2019MaterialisedAnnual report
「As a result of reviewing the outlook for certain product plans, we determined that recovery of the future cash flows could not be expected and recognised the full carrying amount as an impairment loss under extraordinary losses.」
The future cash flows of certain product plans in the metabolomics business were determined to be unrecoverable, and an impairment loss of ¥77,451 thousand was recognised.